Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Anhui Zhifei Longcom

Status and phase: Active, not recruiting; Phase 3

Conditions: Acute Gastroenteropathy Due to Norovirus

Treatments: Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo; Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

Study type: Interventional

Funder types: Industry

Identifiers

NCT06524947

LKM-2023-NoV01

Details and patient eligibility

About

The purpose of the research is to evaluate the protective efficacy, immunogenicity, and safety of quadrivalent recombinant norovirus vaccine (Pichia Pastoris) in people aged 6 weeks to 13 years.A total of 6600 infants and children aged 6 weeks to 13 years old were enrolled in this study, which were divided into 3 age groups: 1400 children (6-13 years old), 2200 toddler (2-5 years old), and 3000 infants (6-23 months old).Subjects of all ages were randomly assigned to the test group and the control group in a 1:1 ratio.All subjects received 3 doses of the experimental vaccine at 30 day intervals.

Full description

Overall design: A multicenter, randomized, double-blind, placebo-controlled trial was designed.

The purpose of the research is to evaluate the protective efficacy, immunogenicity, and safety of quadrivalent recombinant norovirus vaccine (Pichia Pastoris) in people aged 6 weeks to 13 years.A total of 6600 infants and children aged 6 weeks to 13 years old were enrolled in this study, which were divided into 3 age groups: 1400 children (6-13 years old), 2200 toddler (2-5 years old), and 3000 infants (6-23 months old).Subjects of all ages were randomly assigned to the test group and the control group in a 1:1 ratio.All subjects received 3 doses of the experimental vaccine at 30 day intervals.

Protective effectiveness evaluation:All subjects entered the observation period 7 days after completing the first dose of immunization. Stool and/or vomit samples (if applicable) from all AGE cases occurring during the observation period were collected and AGE caused by Norovirus was identified by PCR.Primary protective efficacy was calculated using data from primary endpoint cases that occurred between 7 days after completion of full immunization and the end of the observation period.

Immunogenicity evaluation:For the immunogenic subgroup of subjects (120 subjects before the study number of each age group in a clinical trial site, a total of 360 subjects), blood samples were collected before the first dose of immunization, 31 days after the second dose of immunization, 31 days, 180 days, 1 year and 2 years after the total immunization, and blood samples were 2.5~3.0ml each time.It is used to detect anti-norovirus IgG antibody, tissue Blood group antigen (HBGA) blocking antibody, and to detect the immunogenicity of anti-norovirus.

Safety evaluation:Adverse events (AE) and serious adverse events (SAE) : All enrolled subjects collected AE 30 minutes after each dose of vaccine, enlisted AE 0-7 days, non-enlisted AE 0-30 days, and SAE from the first dose to 180 days after full immunization.

Enrollment: 6,600 patients

Sex: All

Ages: 6 weeks to 13 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 1.The subject's legal guardian agrees to participate in the trial (consent is also required for subjects 8 years of age and older), and can provide proof of legal identity, is fully informed and has signed an informed consent form, and understands and complies with the requirements of the trial protocol to participate in the follow-up visits.
• 2.The age of the subjects on the day of enrollment is not less than 6 weeks old and not more than 13 years old, regardless of gender.
• 3.Those younger than 12 months of age: 2.5kg ≤ birth weight ≤ 4.5kg, 37 weeks ≤ weeks of gestation ≤ 42 weeks, born in normal labor (excluding severe abnormal labor and history of severe asphyxia resuscitation).

Exclusion criteria

• 1.Allergic to or having a history of specific reactions to any component of the investigational vaccine; Previous history of severe allergy to any vaccine or drug (such as anaphylactic shock, laryngeal edema, anaphylactic purpura, local anaphylactic necrosis reaction (Arthus reaction), dyspnea, angioneurotic edema, etc.); People with allergic constitution.
• 2.A history of confirmed norovirus infection within 2 years.
• 3.Have a history of any of the following diseases or are suffering from serious diseases: ① Abnormal coagulation function: such as leukemia, congenital or acquired coagulation factor deficiency, aplastic anemia, thrombocytopenia and receiving anticoagulation therapy; ② Diseases affecting local observation: such as rational jaundice; ③Diseases affecting immune function: a history of congenital or acquired immunodeficiency or autoimmune disease; Uncontrolled lymphoproliferative diseases (such as chronic lymphocytic leukemia, Hodgkin's lymphoma, etc.); No spleen, or splenic surgery history, trauma history; ④Now suffering from infectious diseases: such as tuberculosis, viral hepatitis, etc； ⑤Neurological and psychiatric diseases: epilepsy, congenital brain hypoplasia, brain trauma, brain tumor, infection, brain nerve tissue damage caused by chemical and physical factors, etc., psychiatric history and family history； ⑥Other serious diseases that may interfere with the conduct or completion of the study: severe congenital malformations, severe developmental disorders, severe malnutrition, malignant tumors, congenital cardiovascular, liver, kidney diseases, etc.
• 4.Received blood or blood-related products (other than hepatitis B immunoglobulin) within 1 month prior to enrollment; Long-term use of systemic immunosuppressants or other immunomodulatory drugs within 3 months (defined as use for more than 14 days).
• 5.Have participated or are participating in other clinical trials (including drugs, biologics, or devices) within 3 months prior to enrollment.
• 6.The investigator believes that the subject has any disease or condition that could put the subject at risk, poor adherence or inability to complete the trial as required by the protocol, and conditions that interfere with the evaluation of vaccine response.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

6,600 participants in 6 patient groups, including a placebo group

Infant experimental group (6 weeks -23 months)

Experimental group

Description:

At least 6 weeks old but less than 2 years old.

Treatment:

Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

Infant placebo control group (6 weeks -23 months)

Placebo Comparator group

Description:

At least 6 weeks old but less than 2 years old.

Treatment:

Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo

Toddler experimental group (2-5 years old)

Experimental group

Description:

At least 2 years old but less than 6 years old.

Treatment:

Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

Toddler placebo control group (2-5 years old)

Placebo Comparator group

Description:

At least 2 years old but less than 6 years old.

Treatment:

Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo

Children experimental group (6-13 years old)

Experimental group

Description:

At least 6 years of age but under 14 years of age.

Treatment:

Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

Children placebo control group (6-13 years old)

Placebo Comparator group

Description:

At least 6 years of age but under 14 years of age.

Treatment:

Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo